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INTRODUCTION 
 The major responsibility of an anaesthesiologist is to provide adequate 
ventilation for the patient by  providing unobstructed airway. 
 An anaesthetic technique is safe only when diligent efforts are devoted to 
maintain an intact functional airway. 
 To maintain airway in an anaesthetized or unconscious patient we have 
supraglottic devices like anatomical face mask, laryngeal mask airway, cuffed 
oropharyngeal airway and combitube. 
 Laryngeal mask airway was invented by Dr. ARCHIE BRAIN, United 
Kingdom in 1981. 
 The LMA is an ingenious supraglottic airway device that is designed to 
provide and maintain a seal around the laryngeal inlet for spontaneous ventilation 
and allow controlled ventilation at modest levels of positive pressure. In 
controlled ventilation peak inflation pressure should not exceed 25cm H2O. 
An outstanding feature of LMA is that it provides a rapid clear airway in 
vast majority of patients and it is both faster and easier to insert than a tracheal 
tube. LMA can be used for pediatric and adult patients undergoing daycare 
surgeries. 
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Successful insertion of LMA requires sufficient depth of anaesthesia and 
depression of airway reflexes to avoid gagging, coughing and laryngeal spasm. 
 Propofol is the induction agent most commonly used for insertion of LMA. 
Sevoflurane is a recently introduced volatile anaesthetic agent which allows rapid 
smooth inhalational induction with excellent recovery. 
 This study was being conducted  to compare Sevoflurane and Propofol for 
insertion of laryngeal mask airway in children. This study was carried out in 
Dept. of Anaesthesiology, Stanley medical college, Chennai. 
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AIM OF THE STUDY 
 
The aim of the study is to compare the conditions of  Laryngeal Mask Airway 
insertion in children after induction of anaesthesia with either inhalation of 
sevoflurane or intravenous propofol. 
The time taken for induction, time taken for jaw relaxation, time to LMA 
insertion, hemodynamic parameters, complications during induction and LMA 
insertion are compared. 
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CONCEPTS AND DESIGNS OF LMA 
 
  The LMA fills a niche between the face mask and tracheal tube in terms 
of  both anatomical position and degree of invasiveness. It is manufactured from 
medical grade silicone rubber and is reusable. 
 It consists of 3 main components - Airway tube, inflatable masks and 
mask inflation line. 
 The airway tube is slightly curved to match the oropharyngeal anatomy, 
semi rigid to facilitate atraumatic insertion and semitransparent, so that 
condensation and regurgitated material is visible. A black line runs 
longitudinally along its posterior curvature to aid in insertion.  
The distal inflatable mask is protected by two flexible vertical rubber 
bars, called mask aperture bars, to prevent the epiglottis from entering and 
obstructing the airway. The inflatable mask is oval shaped with a broad, round 
proximal end and a narrower, more pointed distal end. It has an inflatable cuff 
and a semi rigid, concave, shield like back plate. 
 The inner aspect of the mask is called the bowl, which is comprised of the 
distal aperture, mask aperture bars, back plate and the inner aspect of the 
inflatable cuff. 
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 The LMA consists of a curved tube (shaft) connected to an elliptical 
spoon shaped mask at an angle of thirty (30) degrees. 
 At the machine end of the tube is a standard 15 mm connector. 
 There are 7 available sizes. The selection of size is according to the body 
weight of the patient and cuff volume is specified for each size, shown in the 
following table. 
Mask size Body weight (kg) Maximum inflation volume (ml)
1 <5 4 
1.5 5-10 7 
2 10-20 10 
2.5 20-30 14 
3 30-50 20 
4 50-70 30 
5 >70 40 
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LARYNGEAL MASK AIRWAY 
 
 INDICATIONS OF LMA 
1. LMA is used for securing  patient’s airway during general anaesthesia as 
an alternative to endotracheal tube or face mask. 
2.  LMA is useful in patients where maintenance of airway with mask is 
difficult such as edentulous patients, facial injury, burns. 
3.  In case of inability to intubate or ventilate LMA may be life saving either 
as primary means of securing patient’s airway or to facilitate passage of 
ET tube. 
4.  LMA can be used for  diagnostic bronchoscopy as an excellent aid to 
laryngeal inlet. 
5.  During CPR, for rapid securing of patient’s airway, LMA can be used. 
   CONTRAINDICATIONS 
1.  Patients with full stomach. 
2.  Patients with hiatus hernia unless effective measures have been taken to 
empty the stomach. 
3.  Patients with fixed reduced pulmonary compliance such as pulmonary 
fibrosis. 
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4.  Oral, perioral pathology such as tumour, abscess, grossly enlarged tonsil. 
5.  Mouth opening less than 2 cms. 
LMA PREPARATION 
The LMA should be inspected carefully before use. The interior of tube 
must be free from obstruction or foreign particles. The tube should be flexed 
180 degrees and kinking should not occur. The tube should not be bent more 
than 180 degrees, since this could cause permanent damage. Mask aperture 
should be checked and function of the inflation valve should be checked. 
The next step is to inflate the cuff with maximum volume of air that cuff 
should contain. After the cuff is filled it should hold pressure for atleast 2 mins. 
The integrity of the cuff should be verified by inflating it temporarily 
with volume of air 50% greater than recommended maximum volume. Any 
herniation, thinning or asymmetry is an indication to discard LMA. 
The pilot balloon and 15 mm male connector should be checked. 
The cuff should be deflated using LMA deflator and deflated cuff should 
be wrinkle free. 
A water soluble lubricant jelly should be applied to posterior surface of 
cuff just before insertion, taking care to avoid lubricant on anterior surface. 
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INSERTION TECHNIQUE 
 LMA insertion can be considered in the context of swallowing both in 
terms of the space it occupies and the type of reflex response it elicits. The 
insertion technique does not require the use of a laryngoscope or muscle 
relaxants and is designed to imitate the mechanism by which food bolus is 
swallowed. 
 Preparation of the LMA is essential for successful placement. Lubrication 
of the mask should avoid the use of local anaesthetics in order to preserve 
protective reflexes against aspiration. A selection of LMA sizes should be 
available in addition to the one most likely to fit because the anatomical features 
of the larynx cannot always be predicted from the physical examination. Most 
of the induction agents can be used to facilitate placement of the LMA. The 
adequate depth of anaesthesia for LMA placement is significantly less than that 
for tracheal intubation. 
 Several insertion techniques have been described in addition to the 
original technique which was described when the LMA was introduced. 
Standard technique -  The standard technique involves a completely deflated 
LMA, held like a pen guided into the pharynx with the index finger of the 
operator at the junction of the tube and the bowl, with the operator at the head 
of the patient and the LMA aperture facing caudally. With the head extended 
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and the neck flexed by using the hand under occiput, under direct vision, the tip 
of the cuff is pressed upwards against the hard palate. The LMA is advanced 
into the hypopharynx till a resistance is felt. The cuff is then inflated with just 
enough air to seal, to intracuff pressure around 60 cm H2O.  
Partial inflation technique – Another technique is to partially inflate the cuff 
before insertion. This has been found to increase the success rate and may result 
in less sore throat. However, the incidence of downfolding and trapping of the 
epiglottis is increased.  
McNicol’s technique -  A common alternative technique popular in children 
described by McNicol, consists of inserting a partially inflated LMA into the 
pharynx above the epiglottis with the aperture facing cranially, the LMA is then 
turned 180 degrees before advancing it into its final position.  
Awake placement – The laryngeal mask can be inserted in an awake patient 
following topical anaesthesia of the upper airway. This may be useful when 
management of the airway is expected to be difficult or the patient is at 
increased risk for aspiration of gastric contents. 
 
 
 
 
10 
 
The ideal final anatomic position occupied by the classic LMA is as follows: 
• The distal cuff sits in the hypopharynx at the junction of the upper 
oesophagus and respiratory tracts, where it forms a circumferential low 
pressure seal around the glottis. Superiorly, the upper part of the mask 
lies under the base of the tongue, allowing the epiglottis to rest within the 
bowl of the mask at an angle probably determined by the extent to which 
passage of the mask has deflected it downwards. When inflated, it lies 
with the tip resting against the upper esophageal sphincter, the sides 
facing the pyriform fossa with the upper surface behind the base of the 
tongue and the epiglottis pointing upwards. The aperture of a properly 
positioned LMA aligns itself anatomically with the laryngeal inlet. 
• The tip of the LMA cuff lies at a variable depth behind the cricoid 
cartilage, and the posterior surface immediately anterior to C2 to C7 
vertebrae. The laryngeal inlet can be tipped anteriorly by the inflated 
LMA cuff when cricoid pressure is applied; this may explain why blind 
intubation via the LMA is more difficult with cricoid pressure applied. 
The LMA should then be secured after insertion in such a way, so as to 
prevent rotation and movement cranially. 
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SIGNS OF CORRECT PLACEMENT 
• Slight outward movement of the tube upon LMA inflation. 
• Presence of a small oval swelling in the neck around the thyroid and 
cricoid area. 
• No cuff visible in the oral cavity. 
• Expansion of the chest wall on bag compression. 
The confirmation of correct placement is done by monitoring tracings in 
capnography. 
Before taping the LMA in place, a bite block is inserted to stabilise the 
LMA and prevent tube occlusion. 
LMA AND DIFFICULT AIRWAY: 
 Several design features make possible its use as an airway intubator, like 
the wide bore of the LMA tube, the width and elasticity of the aperture bars, the 
angle at which the tube enters the bowl of the mask, anatomical alignment of 
the LMA aperture with the glottis and the low pressure seal allowing 
synchronous patient ventilation. 
 However there are several problems associated with this. The internal 
diameter of the airway tube is too small to accommodate a normal sized tracheal 
tube, and it is too long to ensure that a normal length tracheal tube will penetrate 
the vocal cords. The mask aperture bars interfere with the passage of the 
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tracheal tube. Removal of the LMA may be difficult after successful intubation 
due to the length of the airway tube. Direct blind intubation has a success rate 
around 55%. Success is reduced by cricoid pressure, and is similar for normal 
and abnormal patients. 
 Fiberoptic guided intubation via the LMA has higher success rate and 
causes less trauma. It can be performed directly by inserting the tracheal tube 
over the fiberoptic scope or indirectly using a guide first. Intubating LMA and 
LMA C trach are used as difficult airway gadgets. 
 The manufacturer’s warranty for LMA classic is for 40 uses. Despite high 
capital costs, the LMA is cost effective compared to tracheal tube. 
 
ADVANTAGES OF LMA OVER ENDOTRACHEAL TUBES : 
1. Rapid and easy access of airway. 
2. Laryngoscopy and muscle relaxants are not required. 
3. Hemodynamics and intraocular pressure changes are less than 
endotracheal tube intubation. 
4. Tolerance is better and LMA is less likely to cause injury to the airway 
than endotracheal tube. 
5. Minimal stimulation if left in situ until protective airway reflexes are 
recovered. 
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ADVANTAGES OF LMA OVER FACE MASK: 
1. It is easier to obtain air tight seal with LMA when a good seal with face 
mask is difficult. 
2. The anaesthesiologist’s hands are free and does not require jaw support. 
 
DISADVANTAGES OF LARYNGEAL MASK AIRWAY: 
1. Risk of aspiration and gastric distension. 
2. Patients with glottis or subglottic obstruction cannot be managed with 
LMA. 
3. Appropriate size LMA should be used. Larger or smaller size LMA will 
result in improper seating, leading to cuff leak or airway obstruction due 
to trapping of epiglottis. 
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LMA IN PAEDIATRIC PATIENTS: 
• The laryngeal mask airway can be used in children, including small 
infants. 
• LMA may be particularly helpful in children in whom unusual anatomy 
makes tracheal intubatin difficult. It has been used in Treacher Collins, 
Dandy-walker, Pierre Robin, Goldenhar, Freeman-Sheldon, Beckwith-
Wiedman, and Still’s syndromes. 
• The LMA provides a useful alternative to tracheal tube when it is 
necessary to administer anaesthesia to children with an upper respiratory 
infection. 
• The LMA has been used for children who have anaesthesia for 
radiotherapy and MRI examinations. 
• The LMA has been successfully used for paediatric patients who have 
extracorporeal shock wave lithotripsy. 
• Studies show fewer hypoxic episodes and improved surgical conditions in 
children who are ventilated with the LMA as compared with a face mask. 
• Because the epiglottis in children is relatively large and floppy, the 
likelihood of its being within the mask is greater than in adults. This may 
make blind intubation or intubation over a bougie or guide wire passed 
through the LMA difficult.  
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TYPES OF LMA 
• Reinforced/ flexible LMA (LMA- flexible). 
• LMA specifically designed for tracheal intubation (LMA- Fastrach). 
• Intubating LMA with real time visualization of larynx (LMA- C Trach). 
• Single-use LMA (LMA- Unique). 
• LMA with an integral gastric access venting port (LMA- Proseal). 
 
1. FLEXIBLE LARYNGEAL MASK AIRWAY 
(REINFORCED LMA) 
  It is made from medical grade silicone and rubber and is reusable. It 
consists of a classic LMA connected to a flexible, wire reinforced tube that is 
longer and narrower than the classic LMA. The wire reinforcement prevents 
kinking, the additional length allows the anaesthesia breathing system to be 
connected further from the surgical field and the reduced diameter allows more 
room in the mouth.  
 The cuff and inflation line are identical to the classic LMA. It is available 
in six sizes – 2,2.5,3,4,5 and 6. 
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2. THE INTUBATING LMA – FASTRACH 
  It consists of three parts – the ILMA itself, the tracheal tube and a 
stabilizing rod. 
 The ILMA is a rigid, anatomically curved airway tube made of stainless 
steel with a standard 15mm connector. The tube is wide enough to 
accommodate an 8.0 mm I.D. ETT and short enough to ensure passage of the 
ETT beyond the vocal cords. A rigid handle attached to the tube facilitates one 
handed insertion, removal and most importantly, adjustment of the device’s 
position so that the aperture directly opposes the larynx. It has a single flap, the 
epiglottic elevating  bar. 
 
3. LMA C TRACH: 
 
  LMA C Trach is a modification on the “blind on blind” technique of the 
LMA Fastrach with integrated fiberoptics. 
 It provides a direct view of the larynx with real time visualisation of the 
tracheal tube passing through the vocal cords. It has two integrated fiberoptic 
channels – a light guide to transfer light to illuminate the larynx and a 10,000 
pixel image guide to transfer the image of the larynx of the viewer. 
 There is a modified epiglottic elevating bar which optimizes the light 
source and enables uninterrupted image transmission to the viewer. 
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4. THE DISPOSABLE LMA (UNIQUE) 
 
  The disposable LMA is made of clear medical grade polyvinyl chloride. 
The airway tube is more rigid and the cuff thicker. It is supplied sterile and for 
single use only. It is currently available in sizes similar to the classic LMA. 
 
5. PROSEAL LARYNGEAL MASK AIRWAY (LMA 
PROSEAL) 
 
  The primary design goal was to construct a laryngeal mask with 
improved ventilator characteristics that also offered protection against 
regurgitation and gastric insufflation. The principal new features are a modified 
cuff and a drain tube. The Proseal LMA is a double mask, forming two end-to-
end junctions: one with the respiratory tract and the other with the 
gastrointestinal tract. 
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SEVOFLURANE 
 
CHEMICAL STRUCTURE:    
 Sevoflurane is a halogenated ether  
 
 
PRESENTATION: 
    As a clear, colourless, noninflammable liquid. Has a pleasant, non-
irritant odour. Commercial preparation contains no additives or stabilisers. 
  Molecular weight – 200 
  Boiling point at 760mm Hg – 58.5 C 
  SVP at 20 C – 21.3 kPa 
  Specific gravity at 20 C – 1.520  
  Low solubility in rubber and plastics. 
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MECHANISM OF ACTION: 
Volatile anaesthetics appear to disrupt synaptic transmission, 
especially in the area of the ventrobasal thalamus. 
  The mechanism includes potentiation of GABA and glycine 
receptors and antagonism at NMDA receptors 
  Mode of action at molecular level appears to involve expansion of 
hydrophobic regions in the neuronal membrane, either within the lipid phase or 
within hydrophobic sites in cell membrane proteins. 
 Distribution Partition Coefficients at 37°C 
 
 
 
 
DOSAGE AND ADMINISTRATION: 
 
    Induction of anaesthesia – 5 -7% 
  Maintenance of anaesthesia – 0.5-3%    
  
Blood/Gas 0.63 - 0.69
Water/Gas 0.36 
Olive Oil/Gas 47.54 
Brain/Gas 1.15 
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MAC VALUES FOR ADULTS AND PEDIATRIC PATIENTS 
BY AGE: 
 
Age of Patient (years) Sevoflurane in 100% Oxygen
Sevoflurane in 
65% N2O/35% O2 
0 - 1 months 3.3%                        - 
1 - < 6 months 3.0%                        - 
6 months - < 3 years 2.8% 2.0% 
3 – 12 2.5%                     1.3%   
25 2.6% 1.4% 
40 2.1% 1.1% 
60 1.7% 0.9% 
80 1.4% 0.7% 
 
 
PHARMACOKINETICS: 
 
• Absorption: The major factors affecting the uptake of volatile 
anaeshetic agents are solubility, cardiac output and the concentration 
gradient between the alveoli and venous blood. Sevoflurane is 
exceptionally insoluble in blood; alveolar concentration therefore 
reaches inspired concentration very rapidly, resulting in a rapid 
induction and emergence from anaesthesia.  
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• Distribution: The drug is initially distributed to organs with a high 
blood flow- brain, heart, liver and kidney and later to less well 
perfused organs- muscle, fat and bone. 
• Metabolism: Sevoflurane is metabolised by hepatic cytochrome p-
450IIEI to yield hexafluroisopropanol, which is further conjugated to 
its glucuronide. Approximately 3% of the absorbed dose is 
metabolised. 
• Excretion: Excretion is via the lungs, predominantly unchanged. 
Elimination of sevoflurane is rapid due to its low solubility. Peak 
excretion of hexafluroisopropanol glucuronide occurs within 12 hours; 
the elimination half-life is 55 hrs. 
 
EFFECTS ON ORGAN SYSTEMS: 
 
• Central nervous system – The principal effect is general 
anaesthesia. The drug decreases cerebral vascular resistance and 
cerebral metabolic rate and increases intracranial pressure in a 
dose-related manner. Sevoflurane does not cause epileptiform 
EEG activity. 
• Cardiovascular system – Sevoflurane causes a dose related 
decrease in myocardial contractility and mean arterial pressure; 
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systolic pressure decreases to a greater degree than diastolic 
pressure. It has a little effect on the heart rate and   does not 
sensitize the myocardium to the effect of catecholamines. 
Sevoflurane does not appear to cause coronary steal. 
• Respiratory system – Sevoflurane causes an increase in respiratory 
rate; minute volume remains unchanged. The drug depresses the 
ventilatory response to CO and inhibits hypoxic pulmonary 
vasoconstriction. Sevoflurane appears to relax bronchial smooth 
muscle constricted by histamine or acetylcholine. 
• Genitourinary system – Sevoflurane reduces renal blood flow and 
leads to a modest increase in fluoride ion concentrations. 
 
SIDE EFFECTS: 
• Sevoflurane acts as a trigger agent for the development of 
malignant hyperthermia. 
• Forms compound A  with sodalime in closed circuit only at low 
flow rates, higher temperatures and dessicated sodalime. There are 
no reports of renal toxicity in patients who had received the drug. 
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PROPOFOL 
 
CHEMICAL  STRUCTURE: 
 
  Propofol is 2,6 diisopropyl phenol, a phenol derivative. 
                                             CH (CH3)2 
                                                 OH                                         
                                             CH (CH3)2 
 
PRESENTATION: 
 
  As a white oil-in-water emulsion containing  
   1% propofol 
   10% soyabean oil 
   2.25% glycerol 
   1.25% purified egg phosphatide 
with a pH of 7. 
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MECHANISM OF ACTION: 
 
  Propofol is a relatively selective modulator of gamma 
aminobutyric acid (GABAA) receptors. GABA is the prinicipal inhibitory 
neurotransmitter in the CNS. When activated, the transmembrane chloride 
conductance increases, resulting in hyperpolarization of the postsynaptic cell 
membrane and functional inhibition of the postsynaptic neuron. 
 
DOSAGE  AND ADMINISTRATION: 
 
Induction – 1.5 to 2.5 mg/kg i.v.  The dosage in children is 3-4 mg/kg. 
Maintenance – 100 to 300 µg/kg/min i.v. infusion 
Sedation – 25 to 100 µg/kg/min i.v. 
 Context  sensitive half time for infusion upto 8 hrs is less than 40 mins. 
 
 
 
 
 
25 
 
PHARMACOKINETICS: 
 
• Distribution – Propofol is 97% protein-bound in the plasma; the volume 
of distribution is 700 – 1500 lit. The distribution half-life is 1.3-4.1 
minutes, resulting in brief duration of anaesthesia following bolus 
administration of the drug. 
• Metabolism – Propofol is rapidly metabolised in the liver, primarily to 
inactive glucuronide (49-73%), and sulphate and glucuronide conjugates 
of the hydroxylated metabolite via cytochrome p-450. Extrahepatic 
mechanisms may contribute to the metabolism of the drug. Pulmonary 
uptake of  propofol is significant. 
• Excretion – The metabolites are excreted in urine; 0.3% is excreted 
unchanged. The clearance is 18.8-40.3 ml/kg/min and the elimination 
half-life is 9.3-69.3 minutes. The clearance is decreased in the presence of 
renal failure. 
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EFFECTS ON ORGAN SYSTEMS: 
 
• Central Nervous System – induces hypnosis by enhancing function of the 
GABA activated chloride channel. It decreases  cerebral metabolic rate 
for oxygen (CMRO2), cerebral blood flow and intracranial pressure. 
• Cardiovascular system – causes fall in systolic blood pressure and 
decrease in systemic vascular resistance more than that of thiopentone . 
Decrease in systemic blood pressure is due to both vasodilatation and 
myocardial depression. There is significant reduction in heart rate. 
• Respiratory system – Bolus administration produces apnea of variable 
duration and suppression  of laryngeal reflexes. A maintenance infusion 
of propofol decreases tidal volume and respiratory rate. 
• Gastrointestinal tract – It possess antiemetic property and the incidence of 
postoperative nausea and vomiting is decreased when propofol is 
administered. 
SIDE EFFECTS: 
 
1.  Allergic Reactions – allergic components of propofol include the 
phenyl nucleus and diisopropyl side chain. Patients who develop 
evidence of anaphylaxis on first exposure to propofol may have been 
previously sensitized to diisopropyl radical. Anaphylaxis to propofol 
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during the first exposure is seen in patients with history of other drug 
allergy. 
2.  Bacterial growth – Propofol strongly supports the growth of 
Escherichia Coli and Pseudomonas aeroginosa. For this reason it is 
recommended that 
a)  An aseptic technique should be used when handling 
propofol vial. 
b) Contents of the ampoule should be withdrawn into a 
sterile syringe immediately after opening. 
c)  Contents of the opened ampoule must be discarded if 
they are not used within 6 hrs. 
 
3. Pain on injection 
Pain is the most commonly reported adverse event associated with 
propofol administration. This unpleasant side effect is seen in 10% 
of patients. Prior administration of a potent short acting opioid or 
1% lignocaine decreases the incidence of pain. Changing the 
composition of the carrier fat emulsion of the propofol to long and 
medium chain triglycerides decreases the pain on injection. 
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4. Proconvulsant activity 
The majority of propofol induced seizures during induction of 
anaesthesia or emergence from anaesthesia reflect spontaneous 
excitatory movements which is of subcortical origin. 
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REVIEW OF LITERATURE    
 
1.  Allsop E, Innes P1 (Paed. Anesthesia,1995) have assessed the ease of 
insertion of LMA after induction of anaesthesia with propofol in 60 
healthy unpremedicated children aged between four and nine years. 
Group A – propofol 2.5 mg/kg 
Group B – propofol 3 mg/kg 
Group C – propofol 3.5 mg/kg 
They concluded that it is safe and effective to insert a LMA immediately 
after induction of anaesthesia with propofol 3.5 mg/kg i.v. 
2.  Lopez gil, Mateos Arribas14  (Rev Esp Anestsiol Reanim. 1995) analyzed 
the problems with inserting, maintaining and removing a laryngeal mask 
airway in children. The agent for anaesthetic induction and the mode of 
ventilation were chosen by the anaesthesiologist responsible for each 
case. Correct insertion was achieved on first try in 85% of cases. No 
cases required tracheal intubation or face mask. Cardiovascular 
repercussions were slight and hemodynamic stability was good. 
3.  Lerman J, Davis PJ10 (Anaesthesiology,1996) compared the induction, 
recovery and safety characteristics of sevoflurane in children with 
halothane undergoing ambulatory surgery. Maximum inspired 
concentrations during induction of anaesthesia were 7% sevoflurane and 
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4.3% halothane. They concluded that sevoflurane compared favourably 
with halothane. Early recovery after sevoflurane was predictably more 
rapid than after halothane. The incidence of adverse events was similar 
for both anaesthetics. 
4.  Mori N, Suzuki M17 (Paed. Anes,1996) studied the effects on respiration 
and circulation during induction and recovery with sevoflurane induction 
in paediatric patients.  They found that the incidence of breathholding and 
coughing was less and recovery time was shorter compared to halothane. 
Regarding circulation, slight decrease in blood pressure was observed 
during induction. They suggested that sevoflurane is a suitable agent for 
induction under spontaneous respiration with higher concentrations in 
paediatric anaesthesia. 
5.  Lopez Gil, Brimacombe12 (Anaesthesia,1996) studied the efficacy of 
laryngeal mask airway in 1400 children. Placement was successful in 
90% at the first attempt, 8% at the second attempt and 2% required an 
alternative technique of insertion. There was no major morbidity 
associated with the use of this device. They concluded that LMA is a safe 
and effective form of airway management of infants and children both for 
spontaneous and controlled ventilation using either isoflurane or total 
intravenous anaesthesia with propofol. 
6.  Borgeat A, Fughs T2 (Br J Anaesth,1997) studied the characteristics of 
induction of anaesthesia with 2% propofol. 
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Group A – propofol 3 mg/kg 
Group B – propofol 4 mg/kg 
Group C – propofol 5 mg/kg 
They found that the induction in group B  
was characterized by a short induction time, low incidence of 
spontaneous movements, pain on injection and excellent conditions for 
manual ventilation. 
7.  Lopez Gil, Brimacombe J13 (Paed. Anaes,1999) compared sevoflurane 
and propofol for induction and maintenance of anaesthesia with the 
laryngeal mask airway in children. 
Group A – propofol 3 mg/kg  induction followed by maintenance 
with 5 mg/kg/hr infusion. 
Group B – sevoflurane 7% induction followed by maintenance 
with 1.7% 
They found that the first time insertion success rates were similar in both 
groups, but the insertion time was shorter with sevoflurane. Heart rate 
was higher in the sevoflurane group during induction, maintenance and 
emergence. There were no differences in blood pressure and oxygen 
saturation among the groups. Emergence was more rapid and 
postoperative agitation more common with sevoflurane. They concluded 
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that propofol and sevoflurane are equally effective for induction and 
maintenance of anaesthesia with the LMA in children. 
8.  Ti LK, Chow MY11 (Anesth Analg,1999) compared sevoflurane and 
propofol for LMA insertion in adults.  
Group A – single vital capacity breath of 8% sevoflurane. 
Group B – propofol 3 mg/kg. 
 The LMA was inserted more rapidly in propofol group and 
required fewer attempts. The overall incidence of complications related to 
LMA insertion, especially apnea, was more frequent in the propofol 
group. 
9. Divatia JV, Dasgupta D3 (Indian J of Anaes,2002) compared propofol and 
sevoflurane for LMA insertion in adults. They found that induction time 
was shorter with propofol and shorter time for LMA insertion. No 
difference noted in regard to no. of attempts and complications. 
Hemodynamic responses were stable for both groups. 
10. Ganatra SB, D’Mello5 (Eur J Anaes,2002) studied the conditions for 
insertion of laryngeal mask airway between sevoflurane and propofol 
using fentanyl as a co-induction agent in adults. Both groups received 
fentanyl 1 µg/kg. Patients in sevoflurane group were induced with 8% 
sevoflurane and those in the propofol group with propofol 2.5 mg/kg. 
Excellent or satisfactory conditions were observed in all 30 patients in 
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propofol group and 29 out of 30 patients in sevoflurane group. The time 
taken for LMA insertion is shorter with propofol. Systolic and diastolic 
pressures were lower in propofol group. They concluded that although 
there was a faster induction with propofol- fentanyl, conditions for 
insertion were similar in both groups. Hemodynamic stability was better 
with sevoflurane-fentanyl. The propofol-fentanyl combination was more 
cost-effective. 
11. Siddik SM, Daaboul DG, Baraka21 (Anesth Analg,2005) compared 
sevoflurane-propofol versus sevoflurane or propofol for laryngeal mask 
airway in adults. 
Group I – single VCB of 8% sevoflurane supplemented with 
propofol 1.5 mg/kg 
  Group II – single VCB of 8% sevoflurane 
  Group III – propofol 3 mg/kg 
 The coinduction technique was associated with the most frequent 
incidence of successful LMA insertion at the 1st attempt and infrequent 
incidence of complications like apnea, PONV. 
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MATERIALS AND METHODS 
 
 Sixty patients of ASA physical status 1&2 undergoing elective minor 
surgical procedures below umbilicus lasting less than 60 mins. were included in 
the study. 
Patients belonged to age group of 4 – 12 of both sexes. 
 It was a prospective randomized controlled study. The study was 
approved by institutional ethical committee and parent provided written 
informed consent before induction. 
INCLUSION CRITERIA: 
1. ASA I and II physical status. 
2. No predicted airway difficulty. 
3. Elective minor surgical procedures below umbilicus lasting less than 60 
min. 
EXCLUSION CRITERIA: 
1. Patients at risk of aspiration – upper GI surgery, gastroesophageal          
disease, not fasted. 
2. Patients who require high positive pressure ventilation – eg.  Pulmonary 
fibrosis. 
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3. Known allergy to any anaesthetic. 
MATERIALS: 
1. Classic  Laryngeal mask airways of appropriate size 
2.  Propofol 1%  
3.  Sevoflurane  
4.  Fentanyl and glycopyrrolate 
5.  Appropriate size oral airways 
6.  2,5 and 10 ml syringes 
7. Lubricant jelly. 
PREPARATION OF THE PATIENT: 
 Informed consent from the parent obtained. 
 All patients were fasted as per NPO guidelines. 
 
PREMEDICATION: 
 Syp. Triclofos 60 mg/kg po given 45 min before shifting the child to 
operating room. 
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MONITORS: 
 Standard monitors – 
1. ECG 
2. Pulse oximeter 
3. NIBP 
4.  Precordial stethoscope were used..  
METHODS: 
 Basal heart rate, blood pressure and oxygen saturation were recorded. 
Intravenous access established. 
 Inj. Glycopyrrolate 10µg/kg and Inj. Fentanyl citrate 2 µg/kg i.v. given 
on table. 
 Preoxygenation with 100% O2 done for 3 min. 
 
INDUCTION: 
 Group P- Propofol group. Patients were induced with Inj. Propofol 3 
mg/kg i.v. bolus with simultaneous mask ventilation with N2O/O2 mixture 2:1. 
 Group S- Sevoflurane group. Patients were induced with Sevoflurane 7% 
inhalation in N2O/O2 mixture 2:1. 
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 The time to loss of consciousness and eyelash reflex was noted. Mask 
ventilation was continued until jaw relaxation was attained.  
 After jaw relaxation was attained, LMA insertion done with  standard 
technique by single person in both groups. The size of the LMA selected 
according to the weight of the patient and cuff volume as per manufacturer’s 
instructions. The sizes used in this study were 2 &2.5. 
SIZE OF LMA BODY WEIGHT CUFF VOLUME 
2 10-20 kg 10 ml 
2.5 20-30 kg 14 ml 
 
The time taken for loss of eyelash reflex, time to jaw relaxation were 
noted. The time to LMA insertion and number of attempts required for 
successful insertion were  noted.  Heart rate, blood pressure and oxygen 
saturation were recorded after induction and LMA insertion. Any complications 
during induction or LMA insertion like coughing, gagging, regurgitation, 
vomiting, patient movements, laryngospasm, apnea, traumatic insertion or 
gastric distension were noted. 
 
 
38 
 
TIME TO INDUCTION – time taken from the administration of 
induction agent to loss of consciousness and loss of eyelash reflex. 
TIME TO JAW RELAXATION – time taken from the administration of 
induction agent to relaxation of jaw required to open the mouth. 
TIME TO LMA INSERTION – time taken from the administration of 
induction agent to successful insertion of laryngeal mask airway. 
Once LMA was inserted, adequacy of seal was checked and presence of 
bilateral air entry, gastric distension if any, were noted. A bite block was placed 
and the LMA  secured in position with tapes. 
MAINTENANCE OF ANAESTHESIA: 
 Spontaneous ventilation with N20/O2 mixture 2:1 ratio + Sevoflurane 2% 
with modified Jackson Rees ciruit. 
 Regional blocks were given for intraop and postop analgesia (ilioinguinal 
block for hernia and hydrocele, penile block for circumcision) after fixation of 
LMA. 
LMA REMOVAL: 
 Sevoflurane and N2O were tapered and discontinued at end of surgery 
and the patient was oxygenated for 3 to 5 mins, allowed for spontaneous 
recovery and LMA removed in awake state. 
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 Oropharyngeal suctioning was done in cases who had secretions and 
patient was put in recovery position and observed in operating room for 30 min 
and shifted to recovery room. Patients were observed in recovery room for 60 
min and shifted to postoperative ward. 
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OBSERVATION AND RESULTS 
 
The study was conducted in Paediatric Surgery Operation theatres, 
New Paediatric block, Stanley Medical College Hospital. 
TYPES OF SURGERIES 
SURGERY GROUP P GROUP S TOTAL 
Herniotomy 11 14 25 
PV sac ligation 8 6 14 
Circumcision 9 9 18 
Others 2 1 3 
 
ASA GRADE: 
 All patients of both groups belonged to ASA Grade I and II. 
DEMOGRAPHIC PROFILE: 
  The sample of 60 group was taken for study. Data was expressed as 
mean ±SD or absolute values. Qualitative analysis was compared with Fischer’s 
exact two tailed  test and quantitative analysis was compared with student ‘t’  
test. 
  The level of statistics significant was set up at p < 0.05. 
   
 
41 
 
Table – 1 
Comparison of Age distribution 
Figure: BOX-PLOT compares the age distribution of sevoflurane 
group and propofol group 
 
The mean age in Sevoflurane group is 7.3yrs. and in Propofol group is 
7.73yrs. The data is stastically insignificant (p>0.05)  and thus both 
groups are comparable in terms of age. 
 
Group N Mean 
(Yrs.) 
S.D. Student t-test 
Sevoflurane 30 7.3 2.39 t=0.66, P=0.51 
Propofol 30 7.73 2.66 Not significant 
4.00
6.00
8.00
10.00
12.00
Sevoflurane  Propofol
Box Plot
Groups
Age(yrs) 
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Table – 2 
Comparison of weight distribution 
Figure: BOX-PLOT compares the weight distribution of sevoflurane 
and propofol group 
 
The mean weight  in Sevoflurane group is 20.03 kg and in Propofol 
group is 19.8 kg. The data is statistically insignificant (p>0.05) and 
thus both groups are comparable in terms of weight. 
 
 Group  N Mean 
(Kg) 
S.D. Student t-test 
Sevoflurane 30 20.03 4.31 t=0.21  P=0.82 
Propofol 30 19.8 3.93 Not significant 
10.00
15.00
20.00
25.00
30.00
Sevoflurane  Propofol 
Box Plot
Groups
Weight 
(kg) 
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Table – 3 
Comparison of Sex distribution 
 
Group Female Male Total 
Sevoflurane 4 26 30 
Propofol 9 21 30 
Total 13 47 60 
  
Plots Section 
 
Figure: PLOTS-SECTION shows sex distribution of sevoflurane 
group and propofol group. 
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Table – 4 
Comparison of time to induction 
 
Figure: BOX-PLOT compares the time to induction between 
sevoflurane and propofol group. 
 
The mean time to induction in Sevoflurane group is 30.1 secs 
and in Propofol group is 41.4 secs. The data is stastically 
insignificant (p>0.05). 
 
 
Group N Mean 
(Secs.) 
S.D. Student t-test 
Sevoflurane 30 39.1 6.30 t=1.71, p=0.09 
Propofol 30 41.4 4.17 Not significant 
30.00 
36.25 
42.50 
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48.75 
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Sevoflurane  Propofol
Box Plot
Groups
Time to 
Induction 
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Table – 5 
  Comparison of time to jaw relaxation 
          
Figure:  BOX-BLOT compares the time to jaw relaxation between 
sevoflurane and propofol group. 
 
The mean time to jaw relaxation in Sevoflurane group is 
107.3 secs and in Propofol group is 49.4 secs. The data is 
statistically significant (p<0.05). 
 
 
Group N Mean 
(secs.) 
S.D. Student t- test  
sevoflurane 30 107.3 17.51 t= 17.23, p=0.0001 
propofol 30 49.4 5.69 Significant 
20.00 
55.00 
90.00 
125.00 
160.00 
Sevoflurane Propofol
Box Plot
Groups
 
Time to jaw 
relaxation 
(secs) 
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Table – 6 
Comparison of time to LMA insertion 
 
Figure: BOX-PLOT showing comparison of time to LMA insertion 
between sevoflurane and propofol groups. 
 
The mean time to insertion  in Sevoflurane group is 117.9 secs 
and in Propofol group is 59.3 secs. The data is stastically 
significant (p<0.05) 
 
Group N Mean 
(secs.) 
S.D. Student t-test 
Sevoflurane 30 117.9 19.2 t=15.76, p=0.0001 
Propofol 30 59.3 6.8 Significant 
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The mean base line pulse rate is comparable in both groups as there is no 
significant difference statistically (p >0.05). 
There is statistically significant difference observed (p<0.05) in regard to pulse 
rate between both groups during induction and post insertion.  
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The mean base line mean arterial pressure is comparable in both groups as there 
is no significant difference statistically  (p >0.05). 
There is no statistical significant difference observed  (p >0.05) in regard to 
mean arterial pressure between both groups during induction and post insertion.  
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Table - 9 
Comparison of no. of attempts 
 
 
Figure: Bar Diagram showing comparison of number of attempts 
taken for LMA insertion between Sevoflurane and Propofol groups. 
 
There is no statistically significant difference between two 
groups in regard to no. of attempts required for successful  
LMA insertion (p>0.05). 
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     DISCUSSION 
 
The study shows that the time to induction is less in sevoflurane group 
compared to propofol group(Group S- 39.1 secs vs Group P- 41.1 secs). But this 
is stastically insignificant(p-0.09). In related studies in adults, Divatia et al3 
and Siddik et al21  achieved faster induction with  propofol. The dose of 
propofol used by Divatia et al was 2.45 mg/kg(mean) and the dose of propofol 
used by Siddik et al was 3 mg/kg. 
 The time to jaw relaxation is shorter with propofol in this study (Group P- 
107.3 secs vs Group S- 49.4 secs). This is stastically significant (p- 0.0001). 
This correlates well with the study of Siddik et al21 who had rapid jaw 
relaxation with propofol compared to sevoflurane. 
 In this study, the time to LMA insertion is shorter with propofol (Group 
P-59.3 secs vs Group S-117.9 secs). This is stastically significant (p- 0.0001). 
This result can be correlated with the studies of Divatia et al3, Siddik et al21, Ti 
et al11  who had similar results. But this contradicts the study of Lopez Gil et 
al13, who achieved faster LMA insertion with sevoflurane compared to propofol. 
The dosage of sevoflurane and propofol used are identical to this study. The 
explanation given in their study was that the dose of propofol used would be 
low. 
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 The number of attempts required for LMA insertion was not statistically  
significant between the two groups (p- 0.19). The successful insertion at 1st 
attempt in group S is 83.3% compared to 96.7%  in group P. Fewer attempts 
were required to insert LMA with propofol compared to sevoflurane was shown 
by Ti et al11. Divatia et al3 found no difference between sevoflurane and 
propofol in regard to number of attempts. 
 The hemodyanamic stability is maintained in both groups. There is 
statistically significant difference observed (p<0.05) in regard to pulse rate 
between both groups during induction and post insertion. There is reduction in 
pulse rate in propofol group. In sevoflurane group, rise in pulse rate from  
baseline is noted. The variations in the pulse rate are within acceptable limits 
though there is a statistically significant difference. 
There is no statistical significant difference observed (p >0.05) in regard 
to mean arterial pressure between both groups during induction and post 
insertion. Mori et al17 also found only slight decrease in blood pressure when 
sevoflurane is used for induction. Lopez Gil et al13 also found no differences in 
blood pressure and oxygen saturation among patients in the study comparing 
sevoflurane and propofol for induction and maintenance of anaesthesia using 
laryngeal mask airway in children. 
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Four patients in sevoflurane group had transient apnea during induction. 
The patients recovered spontaneously on ventilation with bag and mask. 
Although it is a non irritant, pleasant smelling volatile anaesthetic agent, 
children rarely have breath holding like episodes with induction dose. In  Mori 
et al17 study, the incidence of breathholding and coughing was less with 
sevoflurane compared to halothane. Ti et al11 also showed more incidence of 
apnea with propofol compared to sevoflurane. In this study, apnea is not noted 
in any cases in propofol group. 
 Four patients in propofol group had movements during induction, which 
is common with the agent. This is correlating with the studies done by Ti et al11 
and Borgeat et al2 who explained that the movements may be partially due to 
pain during injection of propofol. However, no cases had movements during 
induction or LMA insertion in sevoflurane group. 
One patient in propofol group had mild gastric distension while 
ventilating after LMA insertion. LMA  was removed and reinserted and the 
surgery proceeded after confirming adequate seal  but no regurgitation or 
vomiting occurred. In both groups no patient had coughing, gagging, 
regurgitation, vomiting, laryngospasm or desaturation during induction or LMA 
insertion. 
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     SUMMARY 
 
•  We assessed the conditions for insertion of LMA in two groups of 
patient receiving either inhalational sevoflurane or intravenous propofol 
and the following observations were made. 
• There were no significant differences between the two groups in 
demographic data. 
• The time to induction is less with sevoflurane compared to propofol in 
this study, though statistically not significant. 
•  The time to jaw relaxation and  the time to LMA insertion is less with 
propofol,  with statistical significance. 
• The insertion is more successful by 1st attempt in the propofol group. But 
this is not statistically significant. 
• There are few cases who had movements during induction in propofol 
group and few cases had transient apnea during induction in sevoflurane 
group. 
• There is no significant difference between both groups in the incidence of 
coughing, gagging and laryngospasm. 
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• There is significant difference in pulse rate in both groups. The pulse 
rates in propofol group decreased from baseline but within acceptable 
limits. In Sevoflurane group pulse rate increased from baseline during 
induction and LMA insertion, within acceptable limits. 
• The decrease in mean arterial pressure is observed in both groups and is 
not statistically significant. 
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CONCLUSION 
 
In conclusion, Propofol and Sevoflurane are equally effective for LMA 
insertion in children. However, Propofol has a faster insertion time due to early 
onset of jaw relaxation compared to sevoflurane and high success rate in 1st  
attempt for LMA insertion whereas Sevoflurane has better hemodynamic 
stability and less side effects compared to propofol 
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PROFORMA 
  
 Name:  Age/Sex:   IP No:  
Diagnosis:   Surgical procedure:  Anaesthesia:  
     
     GROUP –  
 
PREOP:  PS I/II  Weight:          PR-             BP-             SpO2-  
 
PREMED: 
 
INDUCTION: 
 
LMA SIZE AND CUFF VOLUME: 
 
INDUCTION CHARACTERISTICS:  
 Time to loss of consciousness    -  
 Time to jaw relaxation               -   
 Time to LMA insertion              -  
 No. of attempts            -  
 
 
 
 
INCIDENCE OF COMPLICATIONS:  
 Coughing      -  
 Gagging       -  
 Regurgitation       -  
 Vomiting      -  
 Patient movements    -  
 Laryngospasm      -  
 Apnea       -  
 Trauma(blood staining)  -  
 Gastric distension     -  
 
 
HEMODYNAMIC PARAMETERS: 
 
PARAMETERS BASELINE POSTINDUCTION POST LMA 
INSERTION 
 
Pulse rate    
Blood pressure S/D 
(M) 
   
Oxygen saturation    
 
 
 
 GROUP S
 
Sl 
no. Ip no. Age Sex Weight 
Time to 
induction 
Time to jaw 
relaxation 
Time to LMA 
insertion 
No. of 
attempts Complications 
1. 61436 9 M 21 40 115 125 1 - 
2. 61472 5 M 18 36 102 112 1 - 
3. 61537 6 M 15 40 114 125 1 - 
4. 61582 9 M 21 35 99 110 1 - 
5. 61773 4 F 15 35 90 100 1 - 
6. 61811 11 M 28 40 93 104 1 - 
7. 61819 7 M 20 52 110 136 2 - 
8. 61844 10 F 25 48 124 135 1 - 
9. 61884 6 M 15 54 120 130 1 - 
10. 62042 5 M 19 50 129 140 1 Apnea 
11. 62101 8 M 25 40 120 130 1 - 
12. 62181 7 F 23 42 99 108 1 - 
13. 62188 4 M 17 38 90 100 1 - 
14. 62252 4 M 14 32 94 105 1 - 
15. 62424 12 M 30 36 91 100 1 - 
16. 62505 4 M 16 40 117 125 2 - 
17. 62572 5 M 19 36 103 110 1 - 
18. 62633 7 M 21 36 98 105 1 - 
19. 62751 10 M 29 30 99 110 1 - 
20. 62808 7 M 20 40 128 135 1 - 
21. 62809 12 M 25 45 130 140 1 - 
22. 62875 7 M 15 38 142 150 1 - 
23. 62878 8 M 17 48 149 170 2 - 
24. 63023 9 F 19 38 118 125 2 - 
25. 63244 10 M 21 35 109 120 2 Apnea 
26. 63131 5 M 17 30 70 75 1 - 
27. 63318 7 M 21 36 92 98 1 - 
28. 63160 5 M 16 33 94 105 1 - 
29. 69671 9 M 21 40 96 105 1 Apnea 
30. 69680 7 M 18 30 97 105 1 Apnea 
 
 
 
 
 
 
 
GROUP P 
 
 
Sl no. Ip no. Age Sex Weight Time to induction 
Time to 
jaw 
relaxation 
Time to 
LMA 
insertion 
No. of 
attempts Complications 
1. 61473 10 M 20 45 55 70 1 Movements during induction 
2. 61639 9 F 30 42 56 65 1 - 
3. 61977 6 F 20 48 60 70 1 - 
4. 62039 7 F 21 45 47 55 1 - 
5. 62104 9 M 24 44 46 58 1 - 
6. 62254 4 F 16 42 40 50 1 - 
7. 62344 4 M 11 38 44 56 1 - 
8. 62423 10 M 20 38 53 62 1 - 
9. 62504 4 M 19 39 50 60 1 - 
10. 62385 7 F 21 48 48 56 1 Movements during induction 
11. 63569 5 M 16 50 52 63 1 - 
12. 62632 6 F 24 42 59 70 1 - 
13. 62638 6 M 23 44 56 65 1 - 
14. 62699 10 M 21 40 53 60 1 - 
15. 62700 9 M 20 48 55 65 1 - 
16. 62370 4 M 15 42 54 60 1 - 
17. 62748 5 M 16 40 49 56 1 - 
18. 62877 8 M 19 40 45 55 1 - 
19. 62958 4 M 14 45 52 60 1 Movements during induction 
20. 62961 5 F 14 32 53 60 1 - 
21. 63133 5 M 15 38 52 75 2 Gastric distension 
22. 63135 10 M 21 42 48 59 1 - 
23. 63137 11 M 23 40 46 56 1 - 
24. 63251 11 M 24 40 54 65 1 - 
25. 63306 10 F 21 40 45 54 1 - 
26. 63356 10 M 20 38 42 51 1 - 
27. 63360 12 M 18 45 43 55 1 - 
28. 69674 11 M 23 35 39 45 1 - 
29. 69667 10 M 22 38 41 50 1 Movements during induction 
30. 69671 10 F 23 36 45 55 1 - 
 
 
 
 
 
 
            GROUP S 
Sl 
no. 
Pulse rate Mean arterial Pressure SpO2 
Baseline Post induction 
Post LMA 
insertion Baseline 
Post 
induction 
Post LMA 
insertion Baseline 
Post 
induction 
Post LMA 
insertion 
1. 110 115 115 87 73 73 99 99 99 
2. 130 125 128 71 60 60 99 99 99 
3. 120 128 125 75 70 77 99 99 99 
4. 128 110 112 77 63 63 99 99 99 
5. 138 130 130 71 60 63 99 99 99 
6. 110 106 104 86 73 73 99 99 99 
7. 112 115 110 76 70 74 99 99 99 
8. 106 110 108 91 81 83 99 99 99 
9. 120 125 124 73 67 70 99 99 99 
10. 116 120 122 80 69 67 99 99 99 
11. 125 135 130 86 80 81 99 99 99 
12. 120 130 128 73 60 60 99 99 99 
13. 120 110 118 63 59 60 99 99 99 
14. 130 125 126 60 50 50 99 99 99 
15. 108 110 110 93 82 83 99 99 99 
16. 130 136 135 71 63 63 99 99 99 
17. 126 120 128 66 60 58 99 99 99 
18. 110 108 110 77 70 70 99 99 99 
19. 110 106 108 83 73 74 99 99 99 
20. 120 128 125 83 77 81 99 99 99 
21. 110 120 116 86 77 80 99 99 99 
22. 130 136 130 80 73 73 99 99 99 
23. 128 135 136 86 73 73 99 99 99 
24. 100 108 110 83 73 73 99 99 99 
25. 110 120 118 91 79 83 99 99 99 
26. 120 130 128 80 70 71 99 99 99 
27. 110 124 125 83 73 73 99 99 99 
28. 126 120 124 73 63 67 99 99 99 
29. 110 115 114 73 63 63 99 99 99 
30. 110 112 114 83 72 73 99 99 99 
 
 
 
 GROUP P 
 
Sl 
no. 
Pulse rate Mean arterial Pressure SpO2 
Baselin
e 
Post 
induction 
Post LMA 
insertion Baseline 
Post 
induction 
Post LMA 
insertion Baseline 
Post 
induction 
Post LMA 
insertion 
1. 108 104 106 80 73 78 99 99 99 
2. 110 100 104 72 66 70 99 99 99 
3. 120 108 106 77 70 73 99 99 99 
4. 120 100 102 76 60 60 99 99 99 
5. 120 106 110 83 73 73 99 99 99 
6. 136 120 120 66 60 60 99 99 99 
7. 130 116 120 80 70 73 99 99 99 
8. 120 102 110 87 77 79 99 99 99 
9. 138 125 130 82 73 76 99 99 99 
10. 126 110 112 76 60 60 99 99 99 
11. 138 125 126 74 66 67 99 99 99 
12. 130 116 120 86 73 76 99 99 99 
13. 120 110 112 80 70 72 99 99 99 
14. 116 110 115 90 80 80 99 99 99 
15. 110 100 104 80 70 75 99 99 99 
16. 120 110 116 79 70 75 99 99 99 
17. 118 108 110 80 69 70 99 99 99 
18. 116 110 110 80 70 70 99 99 99 
19. 130 115 120 73 65 67 99 99 99 
20. 120 115 114 70 66 68 99 99 99 
21. 120 104 110 83 70 70 99 99 99 
22. 108 98 100 86 73 73 99 99 99 
23. 110 100 104 83 73 77 99 99 99 
24. 100 90 94 90 79 81 99 99 99 
25. 98 90 92 83 72 73 99 99 99 
26. 118 112 115 83 79 80 99 99 99 
27. 118 108 110 82 77 77 99 99 99 
28. 108 90 92 83 66 69 99 99 99 
29. 120 108 110 73 57 60 99 99 99 
30. 108 96 100 87 72 73 99 99 99 
 
 
